MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1177/02692163261446141

Медицинская библиотека · Palliative medicine · 2026

Implementing psilocybin-assisted therapy in palliative care settings: A survey of stakeholders.

Plourde Louis, Chang Sue-Ling, Nguyen Olivia, Garel Nicolas, Farzin Houman, Stephan Jean-François, Fallu Jean-Sébastien, Dorval Michel, P3A Research Group

СтатьяПеревод в очереди

Аннотация

BACKGROUND

While the adoption of psilocybin-assisted therapy for existential distress offers promising support for patients with life-threatening illnesses, implementing this intervention into palliative care settings presents significant real-world challenges.

AIM: To examine palliative care stakeholders' knowledge and attitudes regarding psilocybin-assisted therapy, and identify barriers and facilitators to its implementation.

DESIGN

We conducted a cross-sectional online survey between April 15 and December 18, 2024. The survey assessed perceived knowledge, attitudes, and perceived barriers and facilitators to the effective integration of psilocybin-assisted therapy into palliative care settings.

SETTING/

PARTICIPANTS

One hundred and twenty-one adults involved in palliative care (physicians, other healthcare professionals, caregivers, and managers) were recruited from Canada's four most populous provinces: Québec, Ontario, Alberta, and British Columbia.

RESULTS

Forty-three percent of stakeholders reported having good knowledge of psilocybin's potential benefits and risks. Attitudes towards psilocybin-assisted therapy were predominantly non-favourable (61%), yet varied across occupational groups (p < 0.0001), with 95% of physicians reporting favourable attitudes. The lack of trained healthcare providers was viewed as the primary barrier to implementation. Key facilitators included further research and developing standardised intervention protocols. Sixty-eight percent of stakeholders endorsed the introduction of psilocybin-assisted therapy during the early stages of the illness trajectory.

CONCLUSIONS

Translating the potential of psilocybin-assisted therapy for existential distress from clinical trials into palliative care settings requires careful consideration and collaboration with stakeholders. Given the significant divergence in perspectives between clinical and non-clinical groups, tailored interprofessional education could help build shared understanding and support effective implementation. Being conducted in Canada, transferability to different regulatory frameworks may be limited.

Для цитирования: Plourde Louis, Chang Sue-Ling, Nguyen Olivia, Garel Nicolas, Farzin Houman, Stephan Jean-François, Fallu Jean-Sébastien, Dorval Michel, P3A Research Group. Implementing psilocybin-assisted therapy in palliative care settings: A survey of stakeholders.. Palliative medicine. 2026. DOI: 10.1177/02692163261446141.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.